This disrupts protein acetylation through two distinct pathways: reduced acetylation of p53 weakens its tumor-suppressive signaling and promotes tumor progression, while decreased acetylation of histone H3 impairs MHC-I antigen presentation, facilitating immune evasion. This evidence concerns the gene TP53 and neoplasm.